Latest news with #Form25
Yahoo
2 days ago
- Business
- Yahoo
Cycurion Announces Continued Listing and Trading of its Common Stock and Warrants on NASDAQ
MCLEAN, Va., June 06, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (Nasdaq: CYCU) ('Cycurion' or the 'Company'), a trusted leader in IT cybersecurity solutions and AI, announces continued listing and trading of its shares of common stock and warrants on NASDAQ. On June 5, 2025, the SEC filed a Form 25 notification of removal from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934 regarding the Units previously listed and registered by Western Acquisition Ventures Corp, the predecessor company prior to the business combination with Cycurion. Cycurion's shares of common stock and warrants continue to be listed and traded on The Nasdaq Global Market and The Nasdaq Capital Market under the symbols 'CYCU' and 'CYCUW', respectively. About CycurionBased in McLean, Virginia, Cycurion (Nasdaq: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies LLC, Cloudburst Security LLC, and Cycurion Innovation, Inc., Cycurion serves government, healthcare and corporate clients with a commitment to securing the digital future. Forward Looking StatementsThis press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion's business. Many factors could cause Cycurion's actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release, including words such as 'continue', 'expect', 'intend', 'will', 'hope', 'should', 'would', 'may', 'potential', and other similar expressions. Such factors could include, among others, those detailed in its Registration Statement on Form S-1 and in its Annual Report on Form 10-K, each as filed with the Securities and Exchange Commission (the 'SEC'). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in those filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and Cycurion does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. Cycurion cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Investor Contact:CORE IRinvestors@ Media Contact:Phone: (703) 555-0123Email: media@
Yahoo
2 days ago
- Business
- Yahoo
Cycurion Announces Continued Listing and Trading of its Common Stock and Warrants on NASDAQ
MCLEAN, Va., June 06, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (Nasdaq: CYCU) ('Cycurion' or the 'Company'), a trusted leader in IT cybersecurity solutions and AI, announces continued listing and trading of its shares of common stock and warrants on NASDAQ. On June 5, 2025, the SEC filed a Form 25 notification of removal from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934 regarding the Units previously listed and registered by Western Acquisition Ventures Corp, the predecessor company prior to the business combination with Cycurion. Cycurion's shares of common stock and warrants continue to be listed and traded on The Nasdaq Global Market and The Nasdaq Capital Market under the symbols 'CYCU' and 'CYCUW', respectively. About CycurionBased in McLean, Virginia, Cycurion (Nasdaq: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies LLC, Cloudburst Security LLC, and Cycurion Innovation, Inc., Cycurion serves government, healthcare and corporate clients with a commitment to securing the digital future. Forward Looking StatementsThis press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion's business. Many factors could cause Cycurion's actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release, including words such as 'continue', 'expect', 'intend', 'will', 'hope', 'should', 'would', 'may', 'potential', and other similar expressions. Such factors could include, among others, those detailed in its Registration Statement on Form S-1 and in its Annual Report on Form 10-K, each as filed with the Securities and Exchange Commission (the 'SEC'). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in those filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and Cycurion does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. Cycurion cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Investor Contact:CORE IRinvestors@ Media Contact:Phone: (703) 555-0123Email: media@ in to access your portfolio
Business Insider
31-05-2025
- Business
- Business Insider
ContextLogic to commence trading on OTC markets, delist from Nasdaq
ContextLogic (LOGC) announced its intention to voluntarily delist from The Nasdaq Global Market at the close of markets on June 2, 2025 and to begin trading on the OTCQB Venture Market of the OTC Markets on June 3, 2025. The company is pleased to announce that the company has been accepted for listing on the OTCQB Venture Market of the OTC Markets and that the company's Class A Common Stock will commence trading on the OTC Markets on Tuesday, June 3, 2025 under the ticker symbol 'LOGC'. Shareholders will not be required to exchange their share certificates or take any other action in connection with the OTC Markets listing as there will be no change in the trading symbol or CUSIP for the Common Stock. The company also announces that as a result of its listing on the OTC Markets, it intends to voluntarily delist its Common Stock from The Nasdaq Global Market and file a Form 25 with the U.S. SEC on or about June 9, 2025. As a result, the company anticipates that the delisting of its Common Stock from Nasdaq will become effective 10 days after the filing, unless otherwise directed by Nasdaq. Confident Investing Starts Here:
NBC News
27-05-2025
- Business
- NBC News
23andMe to delist from Nasdaq, deregister with SEC
23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. The move comes after Regeneron Pharmaceuticals said earlier this month that it will acquire ' substantially all ' of 23andMe's assets for $256 million. The drugmaker came out on top following a bankruptcy auction for 23andMe, a once high-flying genetic testing company that filed for Chapter 11 bankruptcy protection in March. 23andMe said it will file a Form 25 Notification of Delisting with the SEC on or around June 6, which would subsequently remove the stock from listing and registering with the Nasdaq. The company said the Nasdaq had originally informed the company that a Form 25 would be filed in March, but since the exchange has not yet submitted the filing, 23andMe is doing so voluntarily. 23andMe exploded into the mainstream because of its at-home DNA testing kits that allowed customers to examine their genetic profiles. At its peak, the company was valued at around $6 billion. But after going public via a merger with a special purpose acquisition company in 2021, the company struggled to generate recurring revenue and stand up viable research or therapeutics businesses. Regeneron's deal is still subject to approval by the U.S. Bankruptcy Court for the Eastern District of Missouri. Pending approval, it's expected to close in the third quarter of this year.
Yahoo
27-05-2025
- Business
- Yahoo
23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ('23andMe' or the 'Company') (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission (the 'SEC') on or about June 6, 2025, which will remove its securities from listing and registration on Nasdaq. Nasdaq previously suspended the trading of 23andMe's Class A common stock, $0.0001 par value per share (the 'Common Stock'), at the opening of business on March 31, 2025 and notified the Company that a Form 25 would be filed. However, as Nasdaq has not yet made the filing, the Company is doing so voluntarily to permit it to file a Form 15 to deregister with the SEC. 23andMe previously announced on March 23, 2025 that the Company and certain of its subsidiaries initiated voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the Eastern District of Missouri (the 'Court'). Once the Nasdaq delisting on Form 25 becomes effective, 23andMe intends to file a Form 15 to deregister with the SEC. About 23andMe23andMe is a genetics-led consumer healthcare and biotechnology company empowering a healthier future. For more information, please visit Contactpress@ Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words 'believes,' 'anticipates,' 'estimates,' 'plans,' 'expects,' 'intends,' 'may,' 'could,' 'should,' 'potential,' 'likely,' 'projects,' 'predicts,' 'continue,' 'will,' 'schedule,' and 'would' or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements, which could include the following: risks and uncertainties relating to the Company's Chapter 11 case (the 'Chapter 11 case'), including but not limited to, the Company's ability to obtain Court approval with respect to motions in the Chapter 11 case, the effects of the Chapter 11 case on the Company and on the interests of various constituents, Court rulings in the Chapter 11 cases and the outcome of the Chapter 11 cases in general, the debtors' ability to complete the sale of substantially all of their assets to Regeneron Pharmaceuticals, Inc. under Section 363 of the Bankruptcy Code, the length of time the Company will operate under the Chapter 11 case, risks associated with any third-party motions in the Chapter 11 case, the potential adverse effects of the Chapter 11 case on the Company's liquidity or results of operations and increased legal and other professional costs necessary to execute the Company's reorganization; whether the Company will emerge, in whole or in part, from the Chapter 11 case as a going concern; trading price and volatility of the Common Stock; and the continuation of trading of the Common Stock on the OTC Pink Market, including whether broker-dealers will continue to provide public quotes of the Common Stock on the OTC Pink Market, whether the trading volume of the Common Stock will be sufficient to provide for an efficient trading market, and whether quotes for the Common Stock will continue on this market in the future. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the SEC, including under Item 1A, 'Risk Factors' in the Company's most recent Annual Report on Form 10-K, as filed with the SEC, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
